Resonetics

Resonetics operates as a specialized contract manufacturer for life-science and medical-device companies rather than as a branded device developer. Its core position combines laser micromachining with nitinol processing, metal fabrication, microfluidic laminates, and raw-material supply. That breadth allows customers to source multiple stages of component and device production from one partner, including precision tubing, laser cutting, welding, drilling, electropolishing, braiding, and surface treatment. The company describes features as small as two microns and has focused exclusively on life sciences since 2004, narrowing its market emphasis from earlier semiconductor and telecommunications work. Resonetics differentiates through the combination of advanced fabrication capabilities, materials expertise, and an acquisition program aimed at integrated solutions. The 2021 private-equity round of $1.125 billion and a reported $2.25 billion valuation indicate substantial scale for a private manufacturing platform. Its 1,000-5,000 employee range and 16 reported acquisitions reinforce a strategy centered on geographic reach and capability consolidation.

Resonetics shows a multi-year scale-up pattern driven more by acquisitions and manufacturing expansion than by venture-style product launches. Founded in 1987, it shifted its focus decisively toward life sciences in 2004 and has since built a platform around laser micromachining, nitinol, precision metals, microfluidics, and medical-device development services. The 2018 private-equity recapitalization established a capital base involving Regatta Medical and GTCR, followed by a much larger $1.125 billion private-equity round led by The Carlyle Group on Dec 3, 2021. Acquisition activity accelerated from 2020 onward: Hutchinson Technology’s medical business in 2020, Distal Solutions and FISO Technologies in 2021, Hudson Medical Innovations and EaglePicher’s medical-power business in 2021-2022, Agile MV in 2022, Memry in 2023, and Eden Manufacturing, Eden Tool Company, and Resolution Medical in 2025-2026. The January-March 2026 Resolution Medical transaction is an important inflection point because it broadens integrated capabilities in neuromodulation and structural heart. Planned creation of 300 Costa Rican jobs, combined with a 1,000-5,000 employee range, suggests ongoing capacity growth, although precise headcount and revenue trends are not publicly available.